1 2 3 6 VOLUME 16 NUMBER 12 DECEMBER 2015 nature immunology A r t i c l e s liver parenchyma in a well-characterized cohort of 82 patients that had undergone resection of HCC, for whom we had obtained clinical data, histological slides and gene-expression data for the liver parenchyma 13 . We assessed the prevalence of ELSs histologically in 66 subjects (the subset with hematoxylin and eosin (H&E)-stained slides), using a published quantification scale 14 (Fig. 1a and Supplementary  Fig. 1a ). This analysis revealed that in contrast to the relationship between ELS score and colon, breast, lung or skin cancer [3] [4] [5] [6] , a high histological ELS score was associated with increased risk for late recurrence and a trend toward decreased overall survival after HCC resection ( Fig. 1b-d and Supplementary Fig. 1b-d) .
A 12-gene signature has been shown to accurately assess the presence of ELSs in human tissues 1 . Using expression data available for these patients, we found a strong correlation between the histological ELS score and the 12-gene ELS signature (Fig. 1a) , which confirmed its utility for analysis of the liver and enabled us to expand our analysis to include all 82 patients with transcriptome profiles. We found that 15 of 82 patients (18%) had the ELS gene signature in their liver parenchyma ( Fig. 1a) , which was significantly associated with poor survival of patients with HCC after attempted curative surgical resection ( Fig. 1b) , as well as with an increased risk of late recurrence but not early recurrence ( Fig. 1c and Supplementary Fig. 1e ). Of note, multivariable analysis showed that the ELS gene signature was an independent prognostic factor from the 186-gene prognostic-HCC-risk gene signature previously identified for this cohort 13 , as well as the clinical prognostic staging system ( Fig. 1d,e ). Late recurrence, occurring 2 years after surgery, is considered to represent new carcinogenesis from the inflamed liver, while early recurrence, within 2 years of surgery, results from the dissemination of primary tumor cells 15 . Collectively, our analysis of the clinical cohort suggested that ELSs were associated with new HCC development in chronically inflamed and fibrotic or cirrhotic human livers.
Association of ELSs with activation of transcription factor NF-kB
The mechanisms underlying ELS formation in general and in cancer in particular are mostly obscure 2, 16 . To identify signaling pathways that might initiate or facilitate ELS development in HCC, we performed gene-set-enrichment analysis comparing gene expression in the liver parenchyma in patients with high ELS gene signatures and those with low ELS gene signatures. This analysis highlighted the interferon response and signaling via the transcription factor NF-κB as top candidates ( Supplementary Table 1 ). Further analysis of the correlation between activation of NF-κB signaling and hepatic ELSs with three different published NF-κB signatures confirmed the association for NF-κB ( Fig. 1f and Supplementary Fig. 1f ). These findings suggested that activation of the IκB kinase (IKK)-NF-κB signaling pathway might be an important mediator of hepatic ELS generation.
Persistent activation of IKK in hepatocytes induces ELSs
We developed an animal model to assess the contribution of signaling via NF-κB to the generation of ELS and HCC. To activate the IKK-NF-κB signaling pathway in hepatocytes, we bred R26Stop FL Ikk2ca mice (which express a transgene encoding a constitutively active form of IKKβ fused to a Flag tag, as well as a stop cassette flanked by two loxP sites, inserted in the Rosa26 (R26) locus, which serves as the promoter CCL19  CXCL13  CXCL11  CCL8  CXCL10  CXCL9  CCL2  CCL3 CCL18 CCL5 a Figure 1 Hepatic ELSs signify a poor prognosis in human HCC and are associated with NF-κB activation. (a) ELS histological scores (above) of samples from human donors (n = 82; ordered (left to right) according to ELS gene signature), presented as the proportion of portal areas with ELS features (green) (top) and type of ELS (aggregate (Agg), follicle (Fol) or germinal center (GC)), evaluated histologically as the presence or absence (key) of ELS (middle); gaps indicate lack of H&E-stained slides. Bottom, expression of each of the 12 genes in the ELS gene signature 6 ; bar above, presence or absence (key) of a 'high ELS gene signature' (high expression of genes in the signature relative to the mean normalized expression of all samples; defined as described in Online Methods 39, 40 ) . P < 0.001, correlation of histological and bioinformatics ELS scores (Wilcoxon rank-sum test). (b,c) Survival probability (Kaplan-Meier curve; b) and late-recurrence probability (c) after resection of HCC, in patients with a high or low ELS gene signature (key) in the liver parenchyma (n = 82 patients (15 high; 67 low). *P = 0.01 (b) or P = 0.03 (late recurrence, c) (log-rank test). (d,e) Hazard ratios of the ELS gene signature for overall survival (d) and late recurrence (e) in multivariable Cox regression modeling adjusted for 186-gene prognostic HCC risk 13 and American Association for Study of Liver Diseases prognostic stage (AASLD prog stage) 41 (horizontal bars, 95% confidence interval. (f) Enrichment for the NF-κB signature in the cohort of patients in a (ordered (left to right) by enrichment and by presence or absence of the ELS signature (top bar; as in a)), determined by modulation of three experimentally defined sets of NF-κB target genes in HeLa cells 42 , primary human fibroblasts 43 and keratinocytes 43 . Data are representative of one experiment. that drives the transgene) 17 with mice with transgenic expression of Cre recombinase from the promoter of the liver-specific gene encoding albumin (Alb-cre) 18 . The resulting IKKβ(EE) Hep mice expressed the constitutively active form IKKβ(EE) in hepatocytes ( Fig. 2a ) and showed an abundance of nuclear NF-κB and transcriptional activity of NF-κB similar to that of Mdr2-deficient mice, a model of chronic hepatitis 19 , but lower than that of mice treated with tumor-necrosis factor ( Supplementary Fig. 2a-d) ; this suggested that the activity of NF-κB, a major activator of the innate immune system, in IKKβ(EE) Hep mice was similar to that in common forms of chronic hepatitis. The livers of 3-month-old IKKβ(EE) Hep mice lacked overt histopathology ( Supplementary Fig. 2e ). At 7 months, IKKβ(EE) Hep mice had a mild increase in liver macrophages, liver damage markers and hepatocyte proliferation compared with that of age-matched Alb-cre mice ( Supplementary Fig. 2f-k) . Notably, multiple ELSs were apparent in the livers of 7-month-old IKKβ(EE) Hep mice, and they gradually grew in both size and number, while Alb-cre mice did not develop ELSs (Fig. 2b,c) . Immunohistochemical staining revealed that ELSs were composed of T lymphocytes, B lymphocytes, neutrophils (located in the ELS periphery), natural killer cells, macrophages, regulatory T cells and follicular dendritic cells and contained high endothelial venules ( Fig. 2d) , which confirmed that these were true ELSs. We next analyzed ELSs present in the parenchyma of human livers with hepatitis (resected for HCC) and compared their composition of cells of the immune system with that of hepatic ELSs in IKKβ(EE) Hep mice. Histological analysis revealed that ELSs in IKKβ(EE) Hep mice were very similar to their human counterparts ( Fig. 2d) . Flow cytometry of single-cell suspensions of mouse ELSs confirmed the results obtained npg A r t i c l e s by immunohistochemical analysis ( Fig. 2e and Supplementary  Fig. 2l,m) . We also observed compartmentalization of B lymphocytes and T lymphocytes, another characteristic feature of ELSs, in ELSs of IKKβ(EE) Hep mice and human hepatitis ( Supplementary Fig. 2n ). Furthermore, the ELS gene signature was upregulated in the liver parenchymas of IKKβ(EE) Hep mice compared with the expression of these genes in Alb-cre mice (P < 0.05 (two-tailed Students t-test); Supplementary Fig. 2o and Supplementary Table 2 ). Thus, persistent activation of IKK in hepatocytes might be a key mediator of the formation of hepatic ELSs in human hepatitis.
Hepatic ELSs herald aggressive HCCs in IKKb(EE) Hep mice
At 20 months of age, 100% of IKKβ(EE) Hep mice developed HCC, compared with 8% of Alb-cre mice ( Fig. 3a-c) . Histological analysis revealed that approximately half of IKKβ(EE) Hep tumors were welldifferentiated HCCs (WD-HCCs); the remaining tumors were mixed cholangio-hepatocellular carcinomas (HCC-CCCs), indicated by the presence of malignant glandular structures ( Fig. 3d) . Immunostaining of the HCC markers A6 and glutamine synthetase, the proliferation marker Ki67 and matrix-associated collagen IV (whose expression is downregulated in HCC), as well as the presence of metastases to lymph nodes and lungs, confirmed that these were aggressive, malignant HCCs (Supplementary Fig. 3a-c) . Notably, mice with a single allele encoding IKKβ(EE) had a lower number and size of ELSs at 14 months ( Supplementary Fig. 3d,e ), followed by a similar lower HCC load at 20 months, than that of mice with two such alleles ( Supplementary  Fig. 3f,g) ; this underscored the 'NF-κB dose-dependent' ELS phenotype and association between ELSs and HCC, respectively. We also generated mice in which expression of the transgene encoding IKKβ(EE) was driven by the promoter of the gene encoding albumin (Alb-IKKβ(EE) mice). Of note, these mice also had ELSs and mild inflammation, followed by the development of HCC ( Supplementary  Fig. 3h-j) , which confirmed the hepatocarcinogenic effect of constitutive expression of IKKβ(EE) in hepatocytes in a distinct mouse model. Treatment of IKKβ(EE) Hep mice with the hepatic carcinogen diethylnitrosamine (DEN) accelerated the appearance of ELSs (which appeared at 3 months in these conditions) and HCCs (which appeared at 9 months in these conditions), without altering their histological or molecular characteristics ( Supplementary Fig. 3k-r) .
Analysis of the expression of a 16-gene set for assessment of HCC aggressiveness 20 revealed that the expression pattern of HCCs from DEN-treated wild-type mice tended to cluster with that of wild-type livers (seven of ten HCCs), while the expression pattern of HCCs from IKKβ(EE) Hep mice clustered with that of aggressive HCCs from mice with transgenic overexpression of the oncogene Myc in hepatocytes together with germline deletion of the gene encoding the tumor suppressor p53 (Myc-Trp53 −/− ) (eighteen of twenty HCCs) ( Fig. 3e) . The gene-expression pattern of tumors displaying the HCC-CCC morphology, which we detected only in IKKβ(EE) Hep mice and not in DEN-treated (control) mice, clustered with that of the more aggressive group ( Fig. 3e) . Of note, we did not detect a difference between spontaneous HCCs and DEN-induced HCCs in IKKβ(EE) Hep mice in their gene-expression patterns (Fig. 3e) . Arraybased comparative genomic hybridization (CGH) analysis of HCCs from DEN-treated Alb-cre mice (n = 12), DEN-treated IKKβ(EE) Hep mice (n = 11) and 20-month-old IKKβ(EE) Hep mice (n = 13) revealed chromosomal aberrations in all HCC samples (ArrayExpress accession code E-MTAB-3848), which confirmed their neoplastic nature. Mixed HCC-CCC tumors were more complex than were WD-HCCs ( Supplementary Fig. 3s ). To confirm the results of the CGH analysis reported above, we prepared digital PCR probes directed at two genes, Rgs2 and Gab2, and thereby assessed the two most common genomic amplifications. This analysis revealed a 90% concordance with results of the array CGH analysis (Supplementary Fig. 3t ). In addition, analysis of 13 additional IKKβ(EE) Hep HCCs revealed amplification of the Rgs2 copy number in 38% of the HCCs tested and amplification of the Gab2 copy number in 30% of the HCCs tested ( Supplementary  Fig. 3t ). Together these data confirmed that IKKβ(EE) Hep mice developed aggressive HCCs with 100% penetrance. 
HCC progenitor cells first appear inside ELSs and later egress
Careful histological analysis revealed that the earliest malignant hepatocytes (noted at 3 months in DEN-treated mice and at 7 months in untreated IKKβ(EE) Hep mice) appeared first within newly formed ELSs ( Fig. 4a-c) . These malignant hepatocytes were doubly positive for green fluorescent protein (GFP) (expressed from the hepatocytespecific transgene encoding IKKβ(EE)) and E-cadherin ( Fig. 4a) , which confirmed their hepatocyte origin and epithelial phenotype, and they expressed multiple markers of HCC progenitor cells, including A6, GP73 (GOLPH2), Sox9, CD44v6 (ref. 21 ) and CK19 ( Fig. 4b) .
At these earliest time points, HCC progenitor cells were present mainly in ELSs and not elsewhere in the liver parenchyma ( Supplementary  Fig. 4a-c) . GFP expression proved that these cells were derived from hepatocytes expressing the Alb-cre transgene (Supplementary Fig. 4d ). These small clusters gradually grew, initially within ELSs, and later migrated out to form visible tumors ( Fig. 4c and Supplementary  Fig. 4e ). We consistently noted this histological sequence (small groups of cells first appearing within ELSs, followed with gradual coalescence of groups of cells within the follicle boundary, which finally grew out into full-blown HCCs) in all IKKβ(EE) Hep mice of appropriate age in both spontaneous (untreated) groups and DENtreated groups (Supplementary Fig. 4f,g) . To unequivocally prove the neoplastic nature of the epithelial cells that grew within the ELSs, we used laser-capture micro-dissection to collect enriched populations of these cells. Indeed, three of eleven lesions had amplification of Rgs2, and one of eleven lesions had amplification of Gab2 ( Supplementary  Fig. 4h) , which confirmed the neoplastic nature of these lesions and provided a genetic link between the malignant cells that were thriving within the ELSs and the HCCs of IKKβ(EE) Hep mice. Of note, several months after the first appearance of ELSs, we consistently observed clusters of malignant hepatocytes budding from the ELSs (Supplementary Fig. 4i) . These clusters were either in continuity with or slightly separated from the intra-ELS malignant cells (Supplementary Fig. 4i ). To better visualize the egress of clusters of malignant cells, we immunostained serial sections with antibody to CD44v6 (a marker for HCC progenitor cells 21 ) and antibody to the B cell-associated marker B220 and generated three-dimensional reconstructions of ELSs. The result showed clusters of malignant cells budding out of ELSs ( Fig. 4d and Supplementary Video 1) .
Although the transgene encoding IKKβ(EE) was expressed throughout the parenchyma, ELSs were focal (data not shown), which suggested that additional factors triggered the formation of the ELSs. Our finding that the appearance of ELSs was accelerated by the administration of DEN (Supplementary Fig. 3l,m) suggested that tissue damage might be of relevance, either by focal enhancement of activation of NF-κB in hepatocytes or by triggering of another cooperating pro-inflammatory pathway. To investigate this, we analyzed the microanatomical localization of ELSs relative to various liver zones. DEN is converted to its active metabolite in pericentral hepatocytes. Thus, if genotoxic stress were directly involved in npg A r t i c l e s the formation of ELSs, the ELSs would be localized to pericentral regions. Immunostaining of glutamine synthetase (a marker of pericentral hepatocytes) revealed that ELSs were evenly distributed in the three liver zones in untreated IKKβ(EE) Hep mice; however, in DEN-treated IKKβ(EE) Hep mice, ELSs were limited almost entirely to the pericentral zone ( Fig. 4e and Supplementary  Fig. 4j ), which suggested a causal relationship between genotoxic stress and ELS formation.
To investigate whether HCC progenitor cells were also present in ELSs of human patients, we analyzed liver parenchyma from human livers resected for HCC. Triple-immunofluorescence with antibodies to the human HCC markers HSP70 and SOX9 together with antibody to CK19 (which marks reactive ductular cells) revealed the presence of cells with HCC progenitor features within the human ELSs (Fig. 4f) , which attested to a common ELS-related pathogenic mechanism in human HCC and the mouse model.
Depletion of ELSs attenuates mouse HCC
The adaptive immune system is commonly considered a defense mechanism against cancer progression. Accordingly, human HCCs with substantial lymphocytic infiltration have a better prognosis 22 , and Rag1 −/− mice, which lack an adaptive immune system, have more HCCs after treatment with DEN 23 . However, despite its defense function, activation of the immune system can result in various pathologies, including cancer 24, 25 .
To assess the function of ELSs in hepatocarcinogenesis, we bred IKKβ(EE) Hep mice with Rag1 −/− mice, which completely lack B cells and T cells. Consistent with a published report 23 , there was a slightly greater number of HCCs in DEN-treated Rag1 −/− mice than in DENtreated Alb-cre mice ( Fig. 5a-d) . As expected, deletion of Rag1 in IKKβ(EE) Hep mice resulted in complete elimination of ELSs (data not shown). However, in contrast to its pro-tumorigenic effect in Rag1 −/− mice, loss of the adaptive immune system in Rag1 −/− IKKβ(EE) Hep mice substantially attenuated hepatocarcinogenesis; most if not all of the pro-tumorigenic effect of the transgene encoding IKKβ(EE) was lost in the absence of Rag1 (Fig. 5a-d) . The tumors that did develop in Rag1 −/− IKKβ(EE) Hep mice were exclusively typical WD-HCCs and were negative for most markers of HCC progenitor cells ( Fig. 5e-g) .
As expected, HCC progenitor cells in IKKβ(EE) Hep liver were within
ELSs; however, the rare ones occasionally seen in IKKβ(EE) Hep Rag1 −/− mice were in the parenchyma (Fig. 5g) . Comparison of the proliferation, apoptosis and accumulation of the NF-κB subunit RelA (p65) in the nucleus of the HCCs of Rag1 −/− IKKβ(EE) Hep mice and in the well-differentiated HCCs of IKKβ(EE) Hep mice did not reveal differences ( Supplementary Fig. 5a-f) , which challenged the possibility of a cell-autonomous effect of Rag1 deficiency on HCC growth. Together these data suggested that the generation of the focal immunological microniche was dependent on a functional adaptive immune system and that the immunological microniche promoted HCC.
To determine whether ablation of ELS function after the induction of tumors by DEN could still affect HCC formation in IKKβ(EE) Hep mice, we administered antibody to the alloantigen Thy-1.2 (anti-Thy-1.2), to ablate T cells (and potentially also innate lymphoid cells and natural killer cells, which are also reported to respond to such treatment), to mice between 18 and 30 weeks of age; control mice received an isotype-matched control antibody ( Supplementary  Fig. 6a ). Immunostaining of the invariant signaling protein CD3 in livers confirmed almost complete ablation of T cells (Fig. 6a) . Indeed, treatment with anti-Thy-1.2 restricted ELS development (Fig. 6b) , and markedly reduced the multiplicity and burden of HCCs in IKKβ(EE) Hep mice (Fig. 6c-e and Supplementary Fig. 6b-d) . Thus, the adaptive immune system had a strong pro-tumorigenic effect in IKKβ(EE) Hep mice, which took place after acquisition of the initiating tumor mutations.
High expression of growth-promoting cytokines in ELSs
We hypothesized that cytokines secreted by cells of the adaptive immune system, possibly present at high concentrations within ELSs, might underlie their tumor-promoting effects. To identify protumorigenic signals operative within ELSs, we measured the expression of various cytokines in liver parenchyma, ELSs and HCCs from IKKβ(EE) Hep mice and humans with chronic viral hepatitis. Among others, members of the lymphotoxin family, in particular LTβ and LIGHT (TNFSF14), and their downstream effectors, the chemokines CCL17 and CCL20, were prominently overexpressed in human and mouse samples, along with signs of lymphotoxin-driven non-canonical A r t i c l e s activation of the NF-κB pathway (Fig. 7a,b and Supplementary  Fig. 7a-d) . LTβ was also expressed in ELSs of patients with chronic hepatitis (Fig. 7b,c) . Moreover, we noted a correlation between the expression of CCL17 and CCL20 mRNA and that of LTβ in samples from both mice and humans (P < 0.05 (Spearman and Pearson correlation tests, respectively); Supplementary Fig. 7e-h) . This suggested that activation of the receptor for LTβ (LTβR) by LTα, LTβ and/or LIGHT might have a key role in ELS assembly and pro-tumorigenic processes [26] [27] [28] [29] . LTβR is reported to be expressed on hepatocytes, whereas LTα and LTβ are normally expressed in lymphocytes 30 . Indeed, mRNA in situ hybridization revealed that LTβ mRNA was expressed in cells of the immune system, but not epithelial cells, in small ELSs ( Fig. 7d and Supplementary Fig. 7i) .
To identify the specific cell types that expressed LTβ, we used flow cytometry to sort single-cell suspensions of ELSs. This analysis revealed that LTβ mRNA was expressed by both T lymphocytes and B lymphocytes but not by hepatocytes (Supplementary Fig. 7j ). However, in advanced, large ELSs, some of the neoplastic hepatocytes also expressed LTβ, and all full-blown HCCs always expressed LTβ mRNA, as assessed by histology ( Fig. 7d and Supplementary  Fig. 7i) . Notably, when varying degrees of expression were present in malignant hepatocytes within an ELS, there was expression of LTβ mRNA in malignant hepatocytes at the ELS periphery, in particular within the egressing clusters (Fig. 7e,f and Supplementary Fig. 7k,l) . This raised the hypothesis that cells of the immune system within the ELSs might provide paracrine lymphotoxin signals to early HCC progenitor cells, which would be later replaced by an autocrine signal, allowing the malignant hepatocytes to gain independence from the niche. This presumption might be supported by the observation that transgenic overexpression of LTα and LTβ in hepatocytes induces HCC 26 . Notably, HCCs that developed in IKKβ(EE) Hep mice after treatment with anti-Thy-1.2 and in Rag1 −/− IKKβ(EE) Hep livers showed much lower expression of LTβ mRNA than that in similar mice treated with control antibody (Fig. 7g,h and Supplementary  Fig. 7m-p) ; this suggested that exposure of tumor progenitor cells at early stages to niche-derived cytokines rendered them 'addicted' to these cytokines and favored the acquisition of autocrine abilities for production of the same cytokines. 
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To test that hypothesis, we blocked lymphotoxin cytokines through the use of soluble LTβR fused to mouse immunoglobulin Fc fragment (LTβR-Ig) 26 . Furthermore, to determine the time point at which this blockade was most effective, we subjected IKKβ(EE) Hep mice to the following three treatment regimens: at 3-12 weeks of age (early), when LTβ was expressed by cells of the immune system in ELSs; at 13-22 weeks of age (intermediate), when LTβ was expressed by both cells of the immune system and malignant cells in ELSs; and 23-32 weeks of age (late), during which period LTβ had expression similar to that in the intermediate period, yet HCCs were more developed (Supplementary Fig. 8a,b) . Measurement of the expression of various cytokine-encoding genes in liver parenchyma showed lower expression of many genes encoding pro-inflammatory cytokines and lymphotoxin-mediated cytokines in LTβR-Ig-treated IKKβ(EE) Hep mice than in IKKβ(EE) Hep mice treated with the control antibody mouse immunoglobulin G1 (IgG1) ( Fig. 8a) . Of note, the blockade of lymphotoxin signaling was associated with reduced activation of NF-κB in ELS-residing malignant hepatocytes (Supplementary Fig. 8c,d) , which suggested that lymphotoxin signaling enhanced the low level of NF-κB activation induced by the transgene encoding IKKβ(EE). Notably, treatment with LTβR-Ig in the early and intermediate periods substantially diminished the HCC burden ( Fig. 8b and Supplementary Fig. 8e,f) . In contrast, inhibition of LTβR signaling at the late period resulted in a smaller, non-significant effect on HCC number and tumor volume ( Fig. 8b and Supplementary Fig. 8e,f) . As inhibition of lymphotoxin proved ineffective in reducing tumorigenesis beyond 23 weeks of age, we hypothesized that the main inhibitory effect of lymphotoxin blockade might have been in ELSs, in which lymphotoxin is provided mainly by the lymphocytes, rather than in an autocrine manner by niche-external tumor cells. Indeed, histological inspection of early tumorigenesis stages in the late-treatment group revealed a substantial reduction in the number of intra-ELS HCC progenitor cells and in both the multiplicity and size of clusters of egressing cells (Fig. 8c,d and Supplementary Fig. 8g ). This was associated with reduced proliferation of HCC progenitor cells (CDC47 + Sox9 + ) in ELSs upon treatment ( Fig. 8e-g) , which might have accounted for the lower number of ELS-egressing atypical hepatocytes (Fig. 8c,d) . It thus appeared that paracrine lymphotoxin stimulation within ELSs was a critical step in HCC development, amenable to anti-tumor intervention.
DISCUSSION
Our study has revealed a liver tumorigenesis program whereby specialized ELSs, associated with chronic NF-κB activation, fostered atypical hepatocytes that eventually acquired malignant properties. Notably, our study indicated that ELSs, which are commonly present in human livers with HCC, promoted tumor development, rather than counteracting it, as has been demonstrated for several tumor types [3] [4] [5] [6] [7] . This indicates contrasting roles for ELSs in cancer that might be related to the different cancer types or might reflect alternative phenotypes of ELSs. Shortly after ELS expansion and the egress of tumor progenitor cells, we observed distinct tumors with similar chromosomal aberrations, which indicated that the tumors originated from ELS-nested atypical hepatocytes. The pro-tumorigenic effect of ELSs required a competent adaptive immune system that provided lymphocyte-derived cytokines and supported HCC progenitors until they were ready to egress from their niches. Related hepatic ELSs are commonly found in patients with chronic hepatitis who are at risk of developing HCC; hence, these ELSs might constitute a microniche for the population of expanding HCC progenitor cells that support cancer development. Similar to results obtained for our mouse models, these human follicles might form due to constitutive activation of IKK by chronic infection with hepatitis virus (for example, hepatitis B virus 31 or hepatitis C virus 32, 33 ). We may have therefore identified a critical window of immunological-inflammatory action in tumor development: the intra-niche growth of early tumor progenitor cells. The immunological microniche environment seemed to provide tumor progenitor cells with crucial survival and growth factors. Accordingly, preventing niche assembly or interfering with niche function significantly reduced the HCC load in IKKβ(EE) Hep mice. ELSs are unique micro-anatomical structures that are commonly observed in disease states, including cancer 2 . Specifically in the liver, ELSs are associated with chronic hepatitis 11, 12, 34 . Our IKKβ(EE) Hep model has provided functional information about ELSs, showing that they furnished a unique microenvironment that supported growth of tumor progenitor cells. This was confirmed by our studies of humans that showed a higher probability of late recurrence and death after HCC resection in patients with a large number of hepatic ELSs. Of note, late recurrence, occurring 2 years after surgery, is considered to represent de novo carcinogenesis 15 .
Although our experiments with Rag1 −/− mice confirmed published studies showing that certain cells of the adaptive immune system can serve an anti-tumor role in hepatocarcinogenesis (i.e., in the absence of IKK-induced ELS formation), they revealed the substantial protumorigenic potential of cells of the adaptive immune system in specific structures such as the ELS. An obvious difference between the pro-tumorigenic states and anti-tumorigenic states is formation of highly structured microanatomical structures composed of hundreds of cells of the immune system, in which the dominant effect is pro-tumorigenic. It is becoming clear that in lymphatic organs, three-dimensional structures are key for shaping intercellular communication and cooperation among various types of cells of the immune system, frequently involving physical cell-cell interactions that are meticulously orchestrated to generate multiple effector mechanisms and bestow different phenotypes on the interacting cells 35 . Thus, the unique structure of the ELS, as well as structural and composition changes over time, might explain how the adaptive immune system turns from anti-tumorigenic to pro-tumorigenic. The compact structure of the ELS, which groups together large numbers of cells of the immune system, probably suffices to generate a niche containing high concentrations of cytokines and growth factors derived from cells of the immune system that provide a tumor-promoting environment.
The formation of ELSs is thought to depend on innate lymphoid tissue-inducer cells that are recruited to extranodal sites by chemoattracting cytokines 2 . The association between the activation of NF-κB and number of ELSs in human livers and the 100% prevalence of ELSs in IKKβ(EE) Hep livers would suggest that activation of hepatocyte NF-κB (known to occur in chronic hepatitis of diverse etiologies) has a role in ELS formation in the liver, which would link instigation of epithelial innate immunity and focal activation of adaptive immunity 36 .
Although NF-κB was activated throughout the liver of IKKβ(EE) Hep mice, ELSs were focal, which would suggest that additional cues are needed. The finding that ELS formation was significantly accelerated by DEN would suggest that genotoxic stress might have a role in ELS formation. In support of that was the difference in the distribution of ELSs. In untreated IKKβ(EE) hep mice, ELSs were evenly distributed between liver zones, whereas in DEN-treated mice, the ELSs were located mainly in the pericentral zone, where DEN is converted from a pro-carcinogen to a carcinogen that can attack DNA 37 . This joint activation of the NF-κB and DNA damage-response pathways might generate a threshold level of cytokines sufficient to elicit the formation of ELSs. Of note, although a published report has suggested that a persistently active transgene encoding IKK expressed in hepatocytes does not lead to HCC induction 38 , it is plausible that either the expression level was not sufficiently high or that the follow-up time was not long enough. Indeed, we found that mice with a single allele encoding IKKβ(EE) showed diminished tumor load compared with that of mice with two such alleles, which demonstrated that the level of expression of the transgene was important. Furthermore, we noted HCC development in two different strains of mice with transgenic expression of IKK, kept in different facilities.
The egress of tumor cells from the niche in which they first grew was a notable phenomenon we observed in IKKβ(EE) hep mice. Seeds of cancer might germinate in an appropriate microenvironment, yet are capable of leaving the nursing niche and form full-blown malignant tumors only upon acquiring new capabilities. We speculate that the acquisition of niche independence is a hallmark prerequisite of solid tumors initiated within a supportive niche. One specific mechanism we detected in IKKβ(EE) hep mice was the acquisition of autocrine lymphotoxin expression, but others probably also took place. Tumor progenitor cells have been shown to respond to interleukin 6 from resident tissue macrophages, but later acquired autocrine signaling via interleukin 6 that promoted malignant progression 21 . Identifying additional examples of immune system-dependent tumor microniches, as well as their support of tumor progenitor cells and egress mechanisms thereof, might guide effective ways for interfering with these processes for therapeutic purposes.
METHODS
Methods and any associated references are available in the online version of the paper.
